Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health
Type-2 diabetes is a systemic condition with rising global prevalence, disproportionately affecting Indigenous communities worldwide. Recent advances in epigenomics methods, particularly in DNA methylation detection, have enabled the discovery of associations between epigenetic changes and Type-2 di...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2025.1502640/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140981044707328 |
|---|---|
| author | Sarah Munns Sarah Munns Alex Brown Alex Brown Sam Buckberry Sam Buckberry |
| author_facet | Sarah Munns Sarah Munns Alex Brown Alex Brown Sam Buckberry Sam Buckberry |
| author_sort | Sarah Munns |
| collection | DOAJ |
| description | Type-2 diabetes is a systemic condition with rising global prevalence, disproportionately affecting Indigenous communities worldwide. Recent advances in epigenomics methods, particularly in DNA methylation detection, have enabled the discovery of associations between epigenetic changes and Type-2 diabetes. In this review, we summarise DNA methylation profiling methods, and discuss how these technologies can facilitate the discovery of epigenomic biomarkers for Type-2 diabetes. We critically evaluate previous DNA methylation biomarker studies, particularly those using microarray platforms, and advocate for a shift towards sequencing-based approaches to improve genome-wide coverage. Furthermore, we emphasise the need for biomarker studies that include genetically diverse populations, especially Indigenous communities who are significantly impacted by Type-2 diabetes. We discuss research approaches and ethical considerations that can better facilitate Type-2 diabetes biomarker development to ensure that future genomics-based precision medicine efforts deliver equitable health outcomes. We propose that by addressing these gaps, future research can better capture the genetic and environmental complexities of Type-2 diabetes among populations at disproportionate levels of risk, ultimately leading to more effective diagnostic and therapeutic strategies. |
| format | Article |
| id | doaj-art-07e5152f36744daabe693f3b5ae39d5e |
| institution | OA Journals |
| issn | 2296-889X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj-art-07e5152f36744daabe693f3b5ae39d5e2025-08-20T02:29:38ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2025-04-011210.3389/fmolb.2025.15026401502640Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous healthSarah Munns0Sarah Munns1Alex Brown2Alex Brown3Sam Buckberry4Sam Buckberry5The Kids Research Institute Australia, Perth, WA, AustraliaNational Centre for Indigenous Genomics, Australian National University, Canberra, ACT, AustraliaThe Kids Research Institute Australia, Perth, WA, AustraliaNational Centre for Indigenous Genomics, Australian National University, Canberra, ACT, AustraliaThe Kids Research Institute Australia, Perth, WA, AustraliaNational Centre for Indigenous Genomics, Australian National University, Canberra, ACT, AustraliaType-2 diabetes is a systemic condition with rising global prevalence, disproportionately affecting Indigenous communities worldwide. Recent advances in epigenomics methods, particularly in DNA methylation detection, have enabled the discovery of associations between epigenetic changes and Type-2 diabetes. In this review, we summarise DNA methylation profiling methods, and discuss how these technologies can facilitate the discovery of epigenomic biomarkers for Type-2 diabetes. We critically evaluate previous DNA methylation biomarker studies, particularly those using microarray platforms, and advocate for a shift towards sequencing-based approaches to improve genome-wide coverage. Furthermore, we emphasise the need for biomarker studies that include genetically diverse populations, especially Indigenous communities who are significantly impacted by Type-2 diabetes. We discuss research approaches and ethical considerations that can better facilitate Type-2 diabetes biomarker development to ensure that future genomics-based precision medicine efforts deliver equitable health outcomes. We propose that by addressing these gaps, future research can better capture the genetic and environmental complexities of Type-2 diabetes among populations at disproportionate levels of risk, ultimately leading to more effective diagnostic and therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fmolb.2025.1502640/fulltype-2 diabetescardiometabolic diseaseDNA methylationbiomarkersepigenetic clockIndigenous health |
| spellingShingle | Sarah Munns Sarah Munns Alex Brown Alex Brown Sam Buckberry Sam Buckberry Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health Frontiers in Molecular Biosciences type-2 diabetes cardiometabolic disease DNA methylation biomarkers epigenetic clock Indigenous health |
| title | Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health |
| title_full | Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health |
| title_fullStr | Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health |
| title_full_unstemmed | Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health |
| title_short | Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health |
| title_sort | type 2 diabetes epigenetic biomarkers present status and future directions for global and indigenous health |
| topic | type-2 diabetes cardiometabolic disease DNA methylation biomarkers epigenetic clock Indigenous health |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2025.1502640/full |
| work_keys_str_mv | AT sarahmunns type2diabetesepigeneticbiomarkerspresentstatusandfuturedirectionsforglobalandindigenoushealth AT sarahmunns type2diabetesepigeneticbiomarkerspresentstatusandfuturedirectionsforglobalandindigenoushealth AT alexbrown type2diabetesepigeneticbiomarkerspresentstatusandfuturedirectionsforglobalandindigenoushealth AT alexbrown type2diabetesepigeneticbiomarkerspresentstatusandfuturedirectionsforglobalandindigenoushealth AT sambuckberry type2diabetesepigeneticbiomarkerspresentstatusandfuturedirectionsforglobalandindigenoushealth AT sambuckberry type2diabetesepigeneticbiomarkerspresentstatusandfuturedirectionsforglobalandindigenoushealth |